P.A.W. Capital Corp Sells 1,500 Shares of Merck & Co., Inc. (NYSE:MRK)

P.A.W. Capital Corp trimmed its holdings in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 13.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,000 shares of the company’s stock after selling 1,500 shares during the period. Merck & Co., Inc. comprises about 1.3% of P.A.W. Capital Corp’s portfolio, making the stock its 19th largest position. P.A.W. Capital Corp’s holdings in Merck & Co., Inc. were worth $912,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. IMS Capital Management boosted its holdings in shares of Merck & Co., Inc. by 20.1% in the 2nd quarter. IMS Capital Management now owns 16,147 shares of the company’s stock valued at $1,472,000 after buying an additional 2,704 shares in the last quarter. Private Advisor Group LLC boosted its holdings in shares of Merck & Co., Inc. by 7.2% in the 2nd quarter. Private Advisor Group LLC now owns 397,303 shares of the company’s stock valued at $36,222,000 after buying an additional 26,654 shares in the last quarter. Gateway Investment Advisers LLC boosted its holdings in shares of Merck & Co., Inc. by 0.3% in the 2nd quarter. Gateway Investment Advisers LLC now owns 768,265 shares of the company’s stock valued at $70,043,000 after buying an additional 2,541 shares in the last quarter. Allied Investment Advisors LLC boosted its holdings in shares of Merck & Co., Inc. by 1.4% in the 2nd quarter. Allied Investment Advisors LLC now owns 80,484 shares of the company’s stock valued at $7,338,000 after buying an additional 1,121 shares in the last quarter. Finally, PFG Advisors boosted its holdings in shares of Merck & Co., Inc. by 0.8% in the 2nd quarter. PFG Advisors now owns 23,439 shares of the company’s stock valued at $2,137,000 after buying an additional 178 shares in the last quarter. 73.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

MRK has been the topic of a number of recent analyst reports. Cowen raised their price target on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a report on Monday, June 27th. SVB Leerink increased their price objective on shares of Merck & Co., Inc. from $105.00 to $109.00 and gave the company an “outperform” rating in a research report on Monday, September 12th. Mizuho initiated coverage on shares of Merck & Co., Inc. in a research note on Friday, June 24th. They set a “buy” rating and a $100.00 price objective for the company. Daiwa Capital Markets upgraded shares of Merck & Co., Inc. from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $89.00 to $102.00 in a research note on Wednesday, July 6th. Finally, Berenberg Bank upgraded shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and lifted their price objective for the company from $95.00 to $100.00 in a research note on Wednesday, September 14th. Seven research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $98.28.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $84.53 on Thursday. The firm has a market cap of $214.14 billion, a PE ratio of 12.94, a PEG ratio of 1.16 and a beta of 0.33. The firm has a fifty day moving average of $88.96 and a 200 day moving average of $87.74. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.15 and a current ratio of 1.39. Merck & Co., Inc. has a one year low of $71.50 and a one year high of $95.72.

Merck & Co., Inc. (NYSE:MRKGet Rating) last issued its quarterly earnings results on Thursday, July 28th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.67 by $0.20. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. The company had revenue of $14.59 billion during the quarter, compared to analyst estimates of $13.85 billion. During the same quarter in the previous year, the firm earned $1.31 EPS. The firm’s revenue was up 28.0% compared to the same quarter last year. As a group, research analysts predict that Merck & Co., Inc. will post 7.33 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be given a $0.69 dividend. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $2.76 dividend on an annualized basis and a yield of 3.27%. Merck & Co., Inc.’s payout ratio is currently 42.27%.

Merck & Co., Inc. Company Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Stories

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.